|
ACI : Conference-Papers : 2003 : Fraud and Abuse in the Sales and Marketing of Drugs and Medical Devices
3rd National ForumFraud and Abuse in the Sales and Marketing of Drugs and Medical DevicesThe Latest Information from the Front Lines on Current and Emerging Enforcement Hot Spots and Practical Compliance StrategiesWednesday, March 05, 2003
AboutARE YOU SURE YOUR COMPANY'S FRAUD AND ABUSE COMPLIANCE STRATEGY CAN WITHSTAND TODAY'S ENFORCEMENT SCRUTINY?The staggering TAP settlement of October 2001 was by no means the end of the story. Rather, it marked the beginning of a more aggressive enforcement era in the pharmaceutical and medical device arena. With the dust barely settled from the TAP, Bayer and Pfizer settlements, more companies are under investigation for promotion practices and alleged pricing irregularities. Enforcers are employing innovative means to include companies in the ever-widening net of prosecution, from consumer fraud to conspiracy to defraud to false claims. The industry is facing significant pressure to implement, maintain and monitor effective, comprehensive and appropriate compliance strategies. It is clear that no pharmaceutical or device manufacturer will remain a leader without effective in-house compliance policies and a comprehensive understanding of current enforcement activity and allegations. In this volatile arena, even the most sophisticated corporate counsel, sales and marketing executive and compliance officer needs an up-to-the minute understanding of the latest developments…and a forecast for what tomorrow's enforcement agenda holds. American Conference Institute's Third National Forum on Fraud and Abuse in the Sales and Marketing of Drugs and Medical Devices materials will provide you with a sophisticated and comprehensive overview of the most difficult, pressing and costly issues, including effective compliance - from the front lines. The faculty included prosecutors in the most active jurisdictions who will provide timely and critical insight on current civil and criminal theories, how to avoid the microscope of enforcement and emerging trends. In-house counsel from Pfizer, Pharmacia, Wyeth, Boehringer Ingelheim and Sanofi-Synthelabo also shared their experiences in creating and maintaining effective compliance strategies. And that's not all! Along with the key prosecutors and in-house counsel, expert outside attorneys offered practical tips and insights on the hottest issues for today…and tomorrow, including:
Contents & ContributorsAboutARE YOU SURE YOUR COMPANY'S FRAUD AND ABUSE COMPLIANCE STRATEGY CAN WITHSTAND TODAY'S ENFORCEMENT SCRUTINY?The staggering TAP settlement of October 2001 was by no means the end of the story. Rather, it marked the beginning of a more aggressive enforcement era in the pharmaceutical and medical device arena. With the dust barely settled from the TAP, Bayer and Pfizer settlements, more companies are under investigation for promotion practices and alleged pricing irregularities. Enforcers are employing innovative means to include companies in the ever-widening net of prosecution, from consumer fraud to conspiracy to defraud to false claims. The industry is facing significant pressure to implement, maintain and monitor effective, comprehensive and appropriate compliance strategies. It is clear that no pharmaceutical or device manufacturer will remain a leader without effective in-house compliance policies and a comprehensive understanding of current enforcement activity and allegations. In this volatile arena, even the most sophisticated corporate counsel, sales and marketing executive and compliance officer needs an up-to-the minute understanding of the latest developments…and a forecast for what tomorrow's enforcement agenda holds. American Conference Institute's Third National Forum on Fraud and Abuse in the Sales and Marketing of Drugs and Medical Devices materials will provide you with a sophisticated and comprehensive overview of the most difficult, pressing and costly issues, including effective compliance - from the front lines. The faculty included prosecutors in the most active jurisdictions who will provide timely and critical insight on current civil and criminal theories, how to avoid the microscope of enforcement and emerging trends. In-house counsel from Pfizer, Pharmacia, Wyeth, Boehringer Ingelheim and Sanofi-Synthelabo also shared their experiences in creating and maintaining effective compliance strategies. And that's not all! Along with the key prosecutors and in-house counsel, expert outside attorneys offered practical tips and insights on the hottest issues for today…and tomorrow, including:
Contents & ContributorsKEY EVENTS, 2002Ann E. Lewis, Pfizer, Inc. Ethan Posner, Covington & Burling FROM TAP TO TODAY: LESSONS LEARNED Paul E. Kalb, Sidley Austin Brown & Wood Harvey A. Yampolsky, Arent Fox Kintner Plotkin & Kahn PLLC CRITICAL ROADMAP TO THE OIG AND THE PhRMA GUIDELINES Lori G. Baer, Alston & Bird LLP Christiana P. Callahan, Alston & Bird LLP THE FINAL OIG GUIDELINES AND THE PhRMA GUIDELINES: STRATEGIES FOR GETTING YOUR COMPLIANCE PROGRAM TO BE WHERE IT SHOULD BE Robert B. Ramsey, III, Buchanan Ingersoll, P.C. THE MARKETING IMPERATIVE W. Charles Lucas, Pharmacia Corporation HOUSE CALL: PhRMA CODE AND THE AMA GUIDELINES Joseph McMenamin, M.D., J.D., McGuire Woods A HISTORY OF MEDICARE/AWP REIMBURSEMENT Ethan Posner, Covington & Burling Mark H. Lynch, Covington & Burling Frederick G. Herold, Dechert LITIGATION AND ENFORCEMENT UPDATE Ellyn Sternfield, Oregon DOJ Medicaid Fraud Unit David Waterbury, Washington Attorney General's Office WHAT TO DO BEFORE THE GOVERNMENT KNOCKS ON YOUR DOOR: PREVENTIVE TECHNIQUES TO MINIMIZE DAMAGES FROM A CRIMINAL INVESTIGATION Carolyn McElroy, Mintz Levin Cohn Ferris Glovsky & Popeo Howard J. Young, Sonnenschein Nath & Rosenthal CRITICAL CONSIDERATIONS IN USING ADVISORY OPINIONS Robert Homchick, Davis Wright Tremaine LLP ISSUES ARISING IN THE CONTEXT OF RESEARCH Ann E. Lewis, Pfizer, Inc. CAUGHT IN THE WEB? HOW OIG AND PHRMA GUIDELINES AFFECT GENERIC DRUG COMPANIES Joseph Hetrick, Dechert James Berger, Dechert |
Date: Wed, Mar 05, 2003 Location:
New York Pricing:
Option 1: Bundle Package
Binder & CD-ROM Save 299 - Best Value! Total: $699 + $9.95 (shipping & handling) + applicable taxes Option 2: CD-ROM
CD-ROM of program proceedings Total: $499 + $9.95 (shipping & handling) + applicable taxes Option 3: Binder
Printed copy of program proceedings Total: $499 + $9.95 (shipping & handling) |
 |
Publication Details |
Copyright 2007 C5 Group Inc. All Rights Reserved. |